GLP-1 Medicines in the UK: NHS Eligibility, Private Access, and Eating to Protect Muscle
Who qualifies for Mounjaro or Wegovy on the NHS, what private pens cost at named pharmacies today, MHRA fake-pen warnings, and how to protect muscle.
To get tirzepatide (Mounjaro) or semaglutide (Wegovy) on the NHS in England you need a referral through a specialist weight management service, and for tirzepatide in primary care the current phase is restricted to people with a BMI of 35 or more, adjusted for ethnicity, who have been diagnosed with four weight-related health problems. NICE’s own criteria are broader than what is currently being funded. Privately, published prices at named UK pharmacies on 22 September 2026 ran from £110 to £339 a month depending on dose and pharmacy. And the MHRA has issued specific warnings about counterfeit pens sold in the UK.
Last reviewed: 22 September 2026.
This page covers eligibility, access, cost, safety warnings and the muscle question, sourced to NICE, NHS England, the MHRA and peer-reviewed research. It is general information, not medical advice, and nobody here is a clinician. Prescribing decisions are made by a healthcare professional who knows your history.
What NICE actually recommends
NICE has two technology appraisals covering these medicines for weight management, and they are not the same.
Tirzepatide (Mounjaro) — NICE TA1026
Published 23 December 2024, last updated 1 September 2025. Recommendation 1.1, verbatim:
“Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity and the company provides it according to the commercial arrangement.”
And: “Use a lower BMI threshold (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.”
Source: NICE TA1026, chapter 1: Recommendations.
Semaglutide (Wegovy) — NICE TA875
Recommendation 1.1, verbatim:
“Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if: it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and they have at least 1 weight-related comorbidity and: a body mass index (BMI) of at least 35.0 kg/m2, or a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet the criteria for referral to specialist overweight and obesity management services in NICE’s guideline on overweight and obesity management. the company provides semaglutide according to the commercial arrangement.”
The same ethnicity adjustment applies. Source: NICE TA875, chapter 1: Recommendations.
Note the two-year cap on semaglutide. It is in the recommendation itself, and it is routinely left out of articles about NHS access.
Meeting NICE’s criteria is not the same as getting a prescription
This is the gap that causes most of the confusion, and it is stated plainly by NHS England rather than being something we inferred.
NHS England’s page on weight management injections says that tirzepatide is recommended “for eligible adults living with obesity, who present with other weight-related health problems, including: dyslipidaemia (abnormal fat levels in the blood); hypertension (high blood pressure); obstructive sleep apnoea (when your breathing stops and starts while you sleep); cardiovascular disease (heart and blood vessel disease); type 2 diabetes mellitus.”
Then the restriction:
“There is a phased approach to service rollout within primary care settings (for example, GP practices), and initially tirzepatide (Mounjaro) is only available on the NHS to those with the highest clinical need. You may be eligible to access tirzepatide (Mounjaro) in primary care settings if you have been diagnosed with 4 of the weight-related health problems listed above and have a BMI of 35 or more (adjusted for ethnicity).”
Four of the five. Not one, as NICE’s recommendation says. NHS England explains the reasoning as ensuring the service is delivered safely while the NHS builds capacity, and states: “NICE will complete a review at 3 years of the initial implementation period, to determine how access will be managed and who it will be available for.”
For semaglutide, NHS England adds that “Who can take semaglutide may differ depending on which integrated care board you live in.”
Its practical instruction for both: “Check with your local integrated care board to check your eligibility for an assessment.”
| NICE criteria (TA1026 / TA875) | What NHS England says is currently available in primary care | |
|---|---|---|
| Tirzepatide BMI | at least 35 kg/m², lowered by usually 2.5 for the listed ethnic backgrounds | 35 or more, adjusted for ethnicity |
| Tirzepatide comorbidities | at least 1 weight-related comorbidity | 4 of the 5 listed weight-related health problems |
| Semaglutide BMI | 35 or more, or 30–34.9 with referral criteria met | 35 or more (32.5 for listed backgrounds), or 30–34.9 (27.5–32.4) with other criteria met |
| Semaglutide setting | specialist weight management service only | specialist weight management service only; varies by integrated care board |
| Semaglutide duration | maximum of 2 years | — |
Source for the NHS England column: NHS England, Weight management injections, read 22 September 2026.
The two newest UK approvals, and why they are not on the NHS
Two oral GLP-1 medicines were authorised in the UK in 2026. Neither is available through the NHS.
Semaglutide (Wegovy) tablets — approved by the MHRA on 11 June 2026, for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. The MHRA states: “Whilst this tablet is approved for use in the UK, it is not available currently via the NHS. As with all new treatments, decisions on NHS use will follow established processes, including an evaluation by the National Institute for Health and Care Excellence (NICE).” (MHRA, 11 June 2026)
Orforglipron (Foundayo) — authorised on 10 August 2026, making the UK, in the MHRA’s words, “the first country in Europe to approve this GLP-1 tablet for weight management and type 2 diabetes.” Same BMI thresholds: 30 or above, or 27 to 30 with at least one weight-related comorbidity. The MHRA gives the same NHS caveat. (MHRA, 10 August 2026)
An MHRA authorisation means the medicine may lawfully be prescribed in the UK. It does not mean the NHS will fund it. That decision goes to NICE.
What private access costs
The brief we set ourselves was to publish only prices a named pharmacy publishes on its own website, with the date we read them, and never an estimate. Here is what we found on 22 September 2026. These figures will change; check the pharmacy’s own page before relying on them.
Superdrug Online Doctor — Mounjaro, per dose
| Dose | Standard price | New patient price (with the code shown on the page) |
|---|---|---|
| 2.5mg | £179.00 | £143.20 |
| 5mg | £199.00 | £159.20 |
| 7.5mg | £259.00 | £207.20 |
| 10mg | £299.00 | £239.20 |
| 12.5mg | £319.00 | £255.20 |
| 15mg | £339.00 | £271.20 |
The same page listed Superdrug Pharmacy Collect as free and cold delivery at £4.50. Source: Superdrug Online Doctor, Mounjaro, read 22 September 2026.
Numan — Mounjaro, price on a 3-month plan
| Dose | Price per month on a 3-month plan |
|---|---|
| 2.5mg | £110.00 |
| 5mg | £145.20 |
| 7.5mg | £189.20 |
| 10mg | £206.80 |
| 12.5mg | £215.60 |
| 15mg | £233.20 |
Numan’s page notes these are “Subject to clinical suitability” and that “Ongoing monthly pricing varies based on your final plan.” Source: Numan, Mounjaro, read 22 September 2026.
PostMyMeds
Published a single starting figure — Mounjaro “starting from £129.99” — with the note that the starter dose (2.5mg) includes a free sharps bin. Source: PostMyMeds, Mounjaro, read 22 September 2026.
Two things follow from these tables that are worth saying out loud. The price rises steeply with dose, so the cost of month one is not the cost of month eight. And the spread between providers at the same dose was wide on the day we looked — £110 against £179 at 2.5mg, and £233.20 against £339 at 15mg. Neither figure tells you anything about the quality of the clinical service attached.
We did not include Boots Online Doctor or LloydsPharmacy Online Doctor here because neither published a per-dose price on the pages we could read.
The MHRA warnings you should read before buying anything online
Counterfeit pens have reached UK patients
On 24 February 2026 the MHRA published an alert about fake Mounjaro KwikPen 15mg pre-filled pens dispensed by a named pharmacy in Birmingham. The affected pens carried batch number D873576 — which the MHRA notes “is a legitimate batch number for genuine Mounjaro KwikPen 7.5mg, and pens at this strength are not impacted.”
Dr Alison Cave, the MHRA’s Chief Safety Officer, said: “Check the batch number and strength of your KwikPen. If you have one of the affected pens, stop using it straight away.” On the risk: “Testing has confirmed that the identified fake pens do contain tirzepatide, the active substance in Mounjaro, but because the manufacturing conditions are unknown, we cannot confirm that the contents are sterile.”
Because it is injectable, non-sterile contents create an infection risk. The MHRA lists the signs to watch for: “Redness, swelling or warmth around the site of the injection; Pain or discomfort around the site of injection; Fluid leakage from the site of injection; Mild fever, chills, fatigue, and sore throat”, plus possible allergic reaction — “a rash, itching or difficulty breathing”. Its instruction: “If patients experience any symptoms of an infection or allergic reaction, they should seek urgent medical attention.”
The issue came to light “due to faults with the pens, where in all but one case the dose knob came off while in use.” Source: MHRA, Fake Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens, 24 February 2026.
Unregulated sellers
From the MHRA’s December 2025 warning: “Products sold illegally may be fake, contaminated, incorrectly dosed, or contain powerful ingredients not listed on the packaging. These can lead to dangerous side effects, including heart problems, psychological effects and dangerously low blood sugar.”
Its checklist: do not buy prescription-only medicines without a prescription; only buy from registered UK pharmacies or legitimate retailers; check registration with the General Pharmaceutical Council in Great Britain or the Pharmaceutical Society of Northern Ireland; avoid products promoted on social media, “especially those promising ‘quick fixes’, ‘miracle results’, or unusually low prices – these are common signs of illegal sellers”; report suspicious websites or products to the MHRA. (MHRA, 29 December 2025)
Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, gives the simplest test there is: “The simple rule for staying safe is that if you’re offered a GLP-1 medicines without the need for a prescription – walk away.”
Do not increase your own dose
The MHRA’s July 2026 advice: “If you’ve been prescribed a GLP-1 weight-loss medicine, don’t be tempted to fast-track your weight loss by upping your dose. Semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) should only be taken as prescribed by a healthcare professional.”
Retatrutide
The MHRA names it directly: “Don’t be tempted by the online hype around retatrutide. It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.” (MHRA, No summer shortcut for safe weight loss, 24 July 2026)
Side effects, and the ones that need urgent help
From the MHRA’s Drug Safety Update on GLP-1 receptor agonists: gastrointestinal side effects “may affect more than 1 in 10 patients”, including nausea, vomiting, diarrhoea and constipation, which “can persist for several days”. These “are usually non-serious, however can sometimes lead to more serious complications such as severe dehydration, resulting in hospitalisation”. Its advice is to “stay well hydrated by drinking plenty of fluids (such as water) to avoid dehydration”.
It also notes that “hypoglycaemia can occur in non-diabetic patients using some GLP-1RAs for weight management” and that patients should know the symptoms and “urgently seek medical advice should they occur”. Other serious but less common side effects listed are “acute gallstone disease, pancreatitis, and serious allergic reactions”.
On pancreatitis specifically, the MHRA’s patient-facing guidance is concrete: “The main symptom of this is severe pain in the stomach that radiates to the back and doesn’t go away. Anyone who experiences this should seek immediate medical help.”
Sources: MHRA Drug Safety Update, GLP-1 receptor agonists; MHRA, Women on “skinny jabs” must use effective contraception.
Pregnancy, contraception, HRT and surgery
These four are grouped because they are the ones most likely to be missed, and all four come straight from the regulator or from NHS England.
Pregnancy. The MHRA: “These medicines must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding. Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible. This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.” It also reminds women to use effective contraception while taking them “and, in some cases, for up to two months between stopping the medicine and trying to get pregnant.”
Oral contraception on Mounjaro. The MHRA: “Mounjaro may reduce the effectiveness of oral contraceptives in those who are overweight. Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception. This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase.”
HRT. NHS England: “If you’re using tirzepatide (Mounjaro) and taking hormone replacement therapy (HRT), you should consider using patches or gels which are absorbed through the skin. This is because your body may not absorb the HRT whilst using tirzepatide.”
Surgery. NHS England: “Before having a surgical procedure inform your healthcare team, including the anaesthetist, of whether you’re taking liraglutide, semaglutide or tirzepatide (Mounjaro).”
The muscle question, stated honestly
This is where most content about GLP-1 medicines either panics or reassures, and the evidence supports neither.
The most useful recent evidence is a 2026 systematic review and meta-analysis of randomised controlled trials in the International Journal of Obesity, covering seven studies and 821 patients with obesity treated with GLP-1 receptor agonists at obesity doses, compared with placebo. Its results were genuinely two-sided:
- Lean mass as a proportion of total weight improved, by 1.81% (95% CI 1.1 to 2.52; p < 0.00001; I² = 7%).
- But absolute lean mass fell, by 1.74 kg (95% CI −3.04 to −0.45; p < 0.00001; I² = 98%).
- Semaglutide showed the largest absolute lean mass reduction, at −5.44 kg (95% CI −7.07 to −3.81).
The authors’ conclusion: “There is an improvement in body composition due to an increase in lean mass as a proportion of total weight… Our results suggest that lean mass loss should not be considered a limitation for the use of these drugs in patients with obesity. However, it is essential to accompany drug treatment with nutritional and physical exercise interventions to preserve or improve muscle mass and optimize clinical outcomes.”
Two caveats that matter and are usually dropped. First, the heterogeneity on the absolute lean-mass findings was I² = 98%, which is extremely high — the studies disagreed with each other a great deal, so the pooled kilogram figure should be read as a rough central estimate rather than a reliable number. Second, lean mass is not the same as muscle. It includes water, organ tissue and connective tissue, so a fall in lean mass does not translate one-for-one into lost muscle.
Source: Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). International Journal of Obesity, 2026. doi:10.1038/s41366-026-02118-y.
The UK guidance changed because of this
On 9 July 2026 the UK Chief Medical Officers published updated physical activity guidelines. The announcement is explicit that GLP-1 users were part of the reason: “Latest evidence highlights the importance of incorporating strength and balance activities throughout life, including for people taking GLP-1 diabetes and weight-loss drugs.” And: “Those on GLP-1 agonist drugs to combat obesity need to maintain muscle strength.”
The announcement adds: “Strength activities help prevent musculoskeletal conditions and are also essential for those using obesity medication for weight management,” and notes that “Strength can come from everyday tasks like heavy gardening or DIY.”
Source: GOV.UK, New UK CMO activity guidelines show every movement counts, 9 July 2026; Physical activity guidelines: UK Chief Medical Officers’ report, last updated 10 July 2026.
What the NHS actually asks adults to do
| What | The NHS guideline |
|---|---|
| Strengthening activity | “do strengthening activities that work all the major muscle groups (legs, hips, back, abdomen, chest, shoulders and arms) on at least 2 days a week” |
| Aerobic activity | “do at least 150 minutes of moderate intensity activity a week or 75 minutes of vigorous intensity activity a week” |
| How hard | “To get health benefits from strength exercises, you should do them to the point where you need a short rest before repeating the activity.” |
| Can they be combined? | “You can do activities that strengthen your muscles on the same or different days as your aerobic activity – whatever’s best for you.” |
| Does strength work count towards the 150 minutes? | No. “Muscle-strengthening exercises are not always an aerobic activity, so you’ll need to do them as well as your 150 minutes of aerobic activity.” |
Source: NHS, Physical activity guidelines for adults aged 19 to 64, page last reviewed 22 May 2024.
That last row is the one people get wrong. Two strength sessions a week are additional to the 150 minutes, not part of them.
What to eat: what we can and cannot tell you
Here is the honest position. We could not find a protein target for people taking GLP-1 medicines published by the NHS, NICE or the MHRA. The g-per-kilogram figures that appear across GLP-1 diet content — 1.2, 1.5, 1.6 grams per kilogram — do not come from a UK source we were able to verify, and this page will not repeat them. If you want a number, ask the dietitian attached to your weight management service, or ask your prescriber for a referral.
What is sourced is this.
The MHRA’s framing: “Follow doctors’ orders and take your prescribed GLP-1 alongside a healthy diet and a fitness regime. Whether you’re taking it for diabetes management or weight loss, maintaining good nutrition and exercise can help support muscle, bone, and overall health as your calorie intake changes.”
NHS England’s condition of use: “If tirzepatide (Mounjaro) is recommended, you will need to eat a balanced, reduced calorie diet and take part in physical activity regularly whilst taking the medicine.” Both NICE recommendations carry the same phrase — “alongside a reduced-calorie diet and increased physical activity”.
Where the NHS says protein comes from: its balanced-diet guidance groups “Beans, pulses, fish, eggs, meat and other proteins” and states these “are all good sources of protein, which is essential for the body to grow and repair itself. They’re also good sources of a range of vitamins and minerals.” Within that group it gives specific limits and targets that still apply when your appetite is suppressed: limit red and processed meat to 3 portions a week (350 to 500g of cooked meat per portion); “Aim to eat at least 2 portions of fish a week, including 1 portion of oily fish”; choose lean cuts and skinless poultry; pulses are “naturally very low in fat and high in fibre, protein, vitamins and minerals”; unsalted nuts make a good snack but “eat them in moderation”. (NHS, Eating a balanced diet)
Hydration, from the MHRA rather than a wellness blog: stay well hydrated by drinking plenty of fluids such as water, to avoid the dehydration that can follow vomiting and diarrhoea.
Check before changing your diet. The MHRA’s advice applies here in a way most people would not expect: “Always read the patient information leaflet before making dietary changes, as some foods could compromise medicines’ effectiveness.” It gives grapefruit and simvastatin as an example, and warns that intermittent fasting can interact with medicines that need to be taken with food.
If your appetite is suppressed and you are also exhausted, note that fatigue has causes unrelated to the medicine — our guide to the tests to ask your GP for when you are always tired covers what the NHS checks and why. Obstructive sleep apnoea is on NHS England’s own list of weight-related health problems for tirzepatide eligibility, and it is covered there too.
When to get medical help
Seek immediate medical help if you have severe pain in the stomach that radiates to the back and does not go away — the MHRA gives this as the main symptom of acute pancreatitis, which it says is uncommon but can be serious.
Seek urgent medical attention if you have symptoms of infection after injecting (redness, swelling or warmth at the injection site; pain or discomfort; fluid leakage; mild fever, chills, fatigue and sore throat) or of an allergic reaction (rash, itching or difficulty breathing).
Urgently seek medical advice if you have symptoms of hypoglycaemia, which the MHRA notes can occur in people without diabetes who are using some GLP-1 medicines for weight management.
Speak to a healthcare professional and stop the medicine as soon as possible if you become pregnant while taking it.
Speak to a healthcare professional if gastrointestinal side effects are severe or persistent — the MHRA specifically flags the route from vomiting and diarrhoea to severe dehydration and kidney damage requiring hospitalisation.
Report side effects or a suspected fake to the MHRA Yellow Card scheme. The MHRA adds one specific instruction about defective pens: “It is important you do not try to extract any of this medicine if a pen is defective in any way.”
What we did not publish, and why
- A protein target in grams. No NHS, NICE or MHRA source we fetched gives one for people on GLP-1 medicines.
- Expected weight loss percentages. The trial figures are real but belong to specific doses, durations and populations; without the NHS or NICE presenting them to patients, quoting a single headline percentage would mislead more than it informs.
- Average regain after stopping. We found no NHS, NICE or MHRA figure.
- A “cheapest pharmacy” ranking. We publish only what named pharmacies published on the day, and price is not the same as clinical quality.
- Boots and LloydsPharmacy prices. Neither published a per-dose price on the pages we could read on 22 September 2026.
Eating far less, and the nutrients that get squeezed out
A much smaller appetite makes it harder to reach several reference intakes at once, and ten nutrients — copper, folate, iron, selenium, vitamins A, B6, B12, C and D, and zinc — are the only ones that may legally carry an immune claim in Great Britain. Our page on the best foods for your immune system in the UK lists the NHS food sources and reference intake for each, and is a more useful checklist than any supplement aisle. For the digestive side of eating less, see the best foods for gut health in the UK.
Frequently asked questions
Can my GP prescribe Mounjaro for weight loss?
Only within the phased rollout. NHS England states that tirzepatide is prescribed by a specialist weight management service, and that in primary care settings there is a phased approach under which it is “initially only available on the NHS to those with the highest clinical need” — those diagnosed with 4 of the listed weight-related health problems and a BMI of 35 or more, adjusted for ethnicity. NHS England advises checking eligibility with your local integrated care board.
Is the new semaglutide tablet available on the NHS?
Not currently. The MHRA approved the semaglutide (Wegovy) tablet on 11 June 2026 and orforglipron (Foundayo) on 10 August 2026, and stated for both that “Whilst this tablet is approved for use in the UK, it is not available currently via the NHS” and that decisions on NHS use follow established processes including a NICE evaluation.
How do I check a pharmacy is legitimate?
The MHRA advises checking that the pharmacy is registered with the General Pharmaceutical Council for Great Britain, or the Pharmaceutical Society of Northern Ireland for Northern Ireland. Its stated rule of thumb, from Andy Morling of its Criminal Enforcement Unit, is: “if you’re offered a GLP-1 medicines without the need for a prescription – walk away.”
Does Mounjaro stop the contraceptive pill working?
The MHRA states that Mounjaro may reduce the effectiveness of oral contraceptives in those who are overweight, and advises using a non-oral method as well — “especially important for the four weeks after starting Mounjaro and after any dose increase”. NHS England gives the same advice and adds that people on HRT should consider patches or gels absorbed through the skin.
What is retatrutide, and can I buy it?
The MHRA warns against it directly: “Don’t be tempted by the online hype around retatrutide. It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally. These products haven’t been tested for safety, quality or effectiveness and there’s no guarantee that they even contain retatrutide.”
What should I tell an anaesthetist before surgery?
That you are taking the medicine. NHS England’s advice is unambiguous: “Before having a surgical procedure inform your healthcare team, including the anaesthetist, of whether you’re taking liraglutide, semaglutide or tirzepatide (Mounjaro).”
Do I lose the weight again when I stop?
NICE’s semaglutide recommendation builds a stopping point into NHS use — it is recommended only if used for a maximum of 2 years and within a specialist weight management service. NICE does not recommend tirzepatide with a time limit, but says it will review the initial implementation period at 3 years. We have not found an NHS, NICE or MHRA figure for average weight regain after stopping, so we have not published one.
How much protein should I eat on a GLP-1?
We could not find a protein target for people taking GLP-1 medicines published by the NHS, NICE or the MHRA, so this page does not give one. The MHRA’s own wording is that “maintaining good nutrition and exercise can help support muscle, bone, and overall health as your calorie intake changes”. A dietitian, or the team running your weight management service, can set a target for you.
Sources
- NICE TA1026 — Tirzepatide for managing overweight and obesity, Recommendations
- NICE TA875 — Semaglutide for managing overweight and obesity, Recommendations
- NHS England — Weight management injections
- MHRA — Fake Mounjaro (tirzepatide) KwikPen 15mg pre-filled pens (24 February 2026)
- MHRA — No summer shortcut for safe weight loss (24 July 2026)
- MHRA — Urges public to avoid illegal online weight-loss medicines this New Year (29 December 2025)
- MHRA Drug Safety Update — GLP-1 receptor agonists: side effects and potential for misuse
- MHRA — Women on “skinny jabs” must use effective contraception
- MHRA — First GLP-1 tablet for weight loss approved in the UK (11 June 2026)
- MHRA — UK first in Europe to authorise orforglipron (10 August 2026)
- GOV.UK — New UK CMO activity guidelines show every movement counts (9 July 2026)
- GOV.UK — Physical activity guidelines: UK Chief Medical Officers’ report (last updated 10 July 2026)
- NHS — Physical activity guidelines for adults aged 19 to 64 (page last reviewed 22 May 2024)
- NHS — Eating a balanced diet
- Laverde LP et al. — Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of RCTs, International Journal of Obesity, 2026
- Superdrug Online Doctor — Mounjaro (prices read 22 September 2026)
- Numan — Mounjaro (prices read 22 September 2026)
- PostMyMeds — Mounjaro (price read 22 September 2026)